Advertisement

Small study shows COVID-19 vaccine is safe for kids after MIS-C

By HealthDay News
A small study including 15 youths, ages 12 to 18, who recovered from MIS-C and received the Pfizer vaccine at least 90 days after their diagnosis of MIS-C, found all participants tolerated the vaccine with only mild side effects similar to those seen in the general population. File Photo by Ismael Mohamad/UPI | <a href="/News_Photos/lp/c813a89db415bf6a933999d8eacdfd1e/" target="_blank">License Photo</a>
A small study including 15 youths, ages 12 to 18, who recovered from MIS-C and received the Pfizer vaccine at least 90 days after their diagnosis of MIS-C, found all participants tolerated the vaccine with only mild side effects similar to those seen in the general population. File Photo by Ismael Mohamad/UPI | License Photo

COVID-19 vaccines appear to be safe for kids who have had a rare complication called MIS-C after being infected by the coronavirus, according to a new small study.

Some kids get MIS-C -- shorthand for multisystem inflammatory syndrome in children -- four to six weeks after a bout with COVID-19. Many have few or no COVID-19 symptoms, but then develop symptoms of MIS-C, which include fever, abdominal upset, rash and red eyes.

Advertisement

While MIS-C can be fatal, it is treatable with steroids or immune-globulin infusion if diagnosed early.

"Because so little is known about the causes of MIS-C in children previously infected with COVID, many healthcare providers and parents feared that children with a history of MIS-C may redevelop MIS-C or a similar inflammatory problem from the vaccination," study senior author Dr. Tiphanie Vogel said in a news release from Baylor College of Medicine in Houston.

RELATED Hospitalization after COVID-19 vaccination or prior infection is rare

"But our multidisciplinary approach to studying this concern led us to recommend that those patients with a history of MIS-C still get vaccinated to protect themselves from reinfection," said Vogel. She's an assistant professor of pediatrics at the medical school and a researcher at the affiliated Texas Children's Hospital.

Advertisement

This study included 15 youths, ages 12 to 18, who recovered from MIS-C and received the Pfizer vaccine at least 90 days after their diagnosis of MIS-C. They were followed for 9.5 months after vaccination.

All participants tolerated the vaccine with only mild side effects similar to those seen in the general population, the study found.

RELATED Moderna says smaller doses of COVID-19 vaccine effective in children under 6

The findings were published recently in JAMA Network Open.

Researchers are continuing to follow children in the study, as well as a group of those under 12 years of age who received the COVID-19 vaccine after recovering from MIS-C.

The study researchers received funding from Pfizer, a COVID vaccine manufacturer, and Gilead, developer of an antiviral treatment for the disease.

RELATED Many couples disagree about COVID-19 vaccination

More information

There's more on MIS-C at the U.S. Centers for Disease Control and Prevention.

Copyright © 2022 HealthDay. All rights reserved.

RELATED New CDC data shows COVID-19 vaccine protects kids against multiple variants

Latest Headlines

Advertisement
Advertisement

Follow Us

Advertisement